Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Publicity May Have Compounded Chantix Psychiatric Reports, Pfizer Implies

This article was originally published in The Pink Sheet Daily

Executive Summary

Adverse event reports jumped in Q3/Q4 following erratic patient's murder, FDA MedWatch alert and resulting publicity, firm says.

You may also be interested in...



Pfizer, Wyeth Post Lackluster Sales as They Prepare for a Future Together

Pfizer's new business units - which are key to transforming the company - came under Wall Street scrutiny as the company for the first time broke down first quarter sales per unit in an earnings report released April 28

Pfizer, Wyeth Post Lackluster Sales as They Prepare for a Future Together

Pfizer's new business units - which are key to transforming the company - came under Wall Street scrutiny as the company for the first time broke down first quarter sales per unit in an earnings report released April 28

Preparing For A Future With Wyeth, Pfizer Posts Ho-Hum Q1 Results

Although down, numbers are in line with expectations of the company and Wall Street.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068034

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel